focus -WSS

focus

author：focus 2025-10-01 14:20:28 - browse：5918

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Printout prescription drug information shouldn’t go digital

entertainment

WSS

A new House health package & hospitals’ new site

Medicare bonuses could stop drug shortages under Senate plan

Trump surgeon general acknowledges mistakes during Covid

'Make People Better': The CRISPR babies story you probably don't know

Crinetics acromegaly drug succeeds in late

Listen: Biogen's potential pivot, & Illumina's next chapter

focus

focus

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

How generative AI is inspiring dreams of a health data revolution

Anesthesiologist group: stop taking Ozempic before surgery

A rare thyroid diagnosis led to unexpected, all

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Medicare details structure of new drug price negotiation program

How generative AI is inspiring dreams of a health data revolution

Supreme Court strikes down use of affirmative action

High breast density mammograms need follow

hotspot

Snackable artificial intelligence, expert AI, and the pharma industry

Microsoft launches AI tool for clinical documentation through Epic

High breast density mammograms need follow

Mass General, Mayo Clinic look to monetize custom

'Make People Better': The CRISPR babies story you probably don't know

Head of FDA's diagnostics center, who led through Covid, retires

entertainment

entertainment

hotspot

explore